<DOC>
	<DOCNO>NCT00098293</DOCNO>
	<brief_summary>Maraviroc ( UK-427,857 ) , selective reversible CCR5 coreceptor antagonist , show active vitro wide range clinical isolates ( include resistant exist class ) . In HIV-1 infected patient , maraviroc ( UK-427,857 ) give monotherapy 10 day reduce HIV-1 viral load 1.6 log , consistent currently available agent . Safety toleration study 400 subject 28 day 300 mg twice daily . No significant effect see QTc interval . The goal study compare safety efficacy maraviroc ( UK-427,857 ) versus efavirenz , combine two antiretroviral agent , patient previously naive antiretroviral therapy . This study involve approximately 200 center around world achieve total randomized subject population 1071 subject . Patients randomly assign one three group : maraviroc ( UK-427,857 ) 300 mg daily add zidovudine/lamivudine ( 300 mg/150 mg twice daily ) , Maraviroc ( UK-427,857 ) 300 mg twice daily add zidovudine/lamivudine ( 300 mg/150 mg twice daily ) efavirenz ( 600 mg daily ) add zidovudine/lamivudine ( 300 mg/150 mg twice daily ) . The study enroll approximately 18 month period ( 5 month Phase 2b run-in , 13 month Phase 3 ) 96 week treatment . This may extend additional 3 year depend result 96 week . Physical examination perform study entry , week 4 , 8 , 12 , 16 , 20 , 24 , 32 , 40 , 48 , 60 , 72 , 84 96 . Blood sample also take study entry , week 2 , 4 , 8 , 12 , 16 , 20 , 24 , 32 , 40 , 48 , 60 , 72 , 84 96 . Additionally , blood sample draw twice , least 30 minute apart , week 2 48 maraviroc ( UK-427,857 ) pharmacokinetic analysis . As part clinical study blood sample take non-anonymized pharmacogenetic analysis . Patients undergo 12-lead electrocardiogram study entry , week 24 , 48 96 . A computerized tomography ( CT ) scan also perform , select center , study entry week 96 . Patients ask complete symptom distress questionnaire study entry , week 12 , 24 , 48 96 .</brief_summary>
	<brief_title>Trial Maraviroc ( UK-427,857 ) Combination With Zidovudine/Lamivudine Versus Efavirenz Combination With Zidovudine/Lamivudine</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Men woman least 16 year age ( minimum age determine local regulatory authority ) HIV1 RNA viral load great equal 2 , 000 copies/mL A negative urine pregnancy test baseline visit Women Child Bearing Potential ( WOCBP ) Effective barrier contraception WOCBP male Suspected document active , untreated HIV1 relate opportunistic infection ( OI ) condition require acute therapy Treatment active opportunistic infection , unexplained temperature &gt; 38.5 degree Celsius 7 consecutive day Prior treatment efavirenz , zidovudine lamivudine antiretroviral therapy 14 day time Active alcohol substance abuse sufficient , Investigator 's judgment , prevent adherence study medication and/or follow Lactating woman , plan pregnancy trial period Suspected primary ( acute ) HIV1 infection Previous therapy potentially myelosuppressive , neurotoxic , hepatotoxic and/or cytotoxic agent within 30 day prior randomization expect need therapy study period Documented suspect acute hepatitis pancreatitis within 30 day prior randomization Significantly elevate liver enzymes cirrhosis Significant neutropenia , anemia thrombocytopenia Malabsorption inability tolerate oral medication Symptomatic postural hypotension severe cardiovascular cerebrovascular disease Certain medication Genotypic phenotypic resistance efavirenz , zidovudine lamivudine X4 dual/mixedtropic virus repeat assay failure Any clinical condition , Investigator 's judgement , would potentially compromise study compliance ability evaluate safety/efficacy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Aids</keyword>
	<keyword>HIV</keyword>
</DOC>